Celldex Therapeutics (CLDX) Cash from Operations (2010 - 2026)

Celldex Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 65600000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 20.65% year-over-year to 65600000.0 in Q1 2026; TTM through Mar 2026 was 222173000.0, a 29.54% decrease from a year earlier, with the FY2025 full-year figure at 210945000.0, down 33.7% from the prior year.
• Cash from Operations eased to 65600000.0 in Q1 2026 per CLDX's latest filing, from 63945000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 18993000.0 in Q3 2023 and bottomed at 65600000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 32533000.0 (2023), against an average of 37961529.41.
• Across the five-year window, Cash from Operations surged 46.03% in 2023 and slumped 191.35% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 21762000.0 in 2022, then tumbled by 49.49% to 32533000.0 in 2023, then climbed by 0.18% to 32476000.0 in 2024, then tumbled by 96.9% to 63945000.0 in 2025, then slipped by 2.59% to 65600000.0 in 2026.
• Per Business Quant, the three latest CLDX Cash from Operations figures stand at 65600000.0 (Q1 2026), 63945000.0 (Q4 2025), and 48623000.0 (Q3 2025).